It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
A perimetastatic capsule is a strong positive prognostic factor in liver metastases, but its origin remains unclear. Here, we systematically quantify the capsule’s extent and cellular composition in 263 patients with colorectal cancer liver metastases to investigate its clinical significance and origin. We show that survival improves proportionally with increasing encapsulation and decreasing tumor-hepatocyte contact. Immunostaining reveals the gradual zonation of the capsule, transitioning from benign-like NGFRhigh stroma at the liver edge to FAPhigh stroma towards the tumor. Encapsulation correlates with decreased tumor viability and preoperative chemotherapy. In mice, chemotherapy and tumor cell ablation induce capsule formation. Our results suggest that encapsulation develops where tumor invasion into the liver plates stalls, representing a reparative process rather than tumor-induced desmoplasia. We propose a model of metastases growth, where the efficient tumor colonization of the liver parenchyma and a reparative liver injury reaction are opposing determinants of metastasis aggressiveness.
Cancer liver metastases can be encapsulated by a fibrotic stroma. Here the authors use digital pathology to generate spatial growth pattern maps of colorectal cancer liver metastasis and show that prognosis depends on the degree of fibrotic encapsulation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 Karolinska Institutet, Department of Biosciences and Nutrition, Huddinge, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Karolinska University Hospital, Department of Clinical Pathology and Cancer Diagnostics, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705); Karolinska Institutet, Department of Laboratory Medicine, Division of Pathology, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
2 Karolinska Institutet, Department of Biosciences and Nutrition, Huddinge, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
3 Skåne University Hospital, Department of Clinical Genetics, Pathology and Molecular Diagnostics, Medicinsk Service, Lund, Sweden (GRID:grid.411843.b) (ISNI:0000 0004 0623 9987)
4 Karolinska University Hospital, Department of Clinical Pathology and Cancer Diagnostics, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705)
5 Uppsala University, Department of Immunology, Genetics and Pathology, Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457)
6 Karolinska Institutet, Pancreatic Cancer Research Laboratory, Department of Clinical Science, Intervention and Technology, Hudinge, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
7 Karolinska Institutet, Department of Oncology-Pathology, Solna, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
8 Karolinska Institutet, CRISPR Functional Genomics, SciLifeLab and Department of Medical Biochemistry and Biophysics, Solna, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
9 Karolinska Institutet, Department of Medicine Huddinge, Huddinge, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
10 Karolinska Institutet, Karolinska University Hospital, Department of Clinical Science, Intervention and Technology, Division of Surgery, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705)
11 Translational Cancer Research Unit (GZA Hospitals and University of Antwerp), Antwerp, Belgium (GRID:grid.5284.b) (ISNI:0000 0001 0790 3681)
12 Uppsala University, Department of Immunology, Genetics and Pathology, Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457); University of Bergen, Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Bergen, Norway (GRID:grid.7914.b) (ISNI:0000 0004 1936 7443)
13 Karolinska Institutet, Department of Biosciences and Nutrition, Huddinge, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Theme Cancer, Karolinska University Hospital, 17 176, Solna, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705)